| Expression pattern: |
UP |
| Associated gene: |
TMED10, ATG4B, AGO2 |
| Associated microRNA: |
- |
| Biological function: |
induces oxaliplatin resistance and decreases chemosensitivity by promoting autophagy (via exosomal transfer). |
| Molecular mechanism: |
circATG4B encodes a protein (circATG4B-222aa) that competitively binds TMED10, preventing TMED10 from binding ATG4B, thereby increasing autophagy and inducing chemoresistance. |
| Biological pathway or process: |
autophagy (promotes); chemoresistance (promotes); drug resistance (promotes) |
| Detected method: |
Q
|
| Validation methods: |
divergent primers PCR; Sanger Sequencing; RNase R Treatment; RT-qPCR; FISH / smFISH; RIP (RNA Immunoprecipitation); Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; IF (Immunofluorescence); Western Blot; TEM; In Vivo Animal Model; IHC (Immunohistochemistry); Clinical Sample Validation; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circATG4B expression is associated with worse disease-free survival and reduced benefit from oxaliplatin treatment in CRC patients. |
| Description: |
circATG4B is up-regulated in oxaliplatin-resistant CRC (notably enriched in exosomes) and is associated with poorer DFS under oxaliplatin treatment. Mechanistically, circATG4B promotes oxaliplatin resistance by promoting autophagy, largely via encoding circATG4B-222aa that binds TMED10 and relieves TMED10-mediated inhibition of ATG4B. |
| Confidence score: |
0.8557 |